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T Cell Trafficking through  
Lymphatic vessels
Morgan C. Hunter1, Alvaro Teijeira2 and Cornelia Halin1*
1 Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland, 2 Immunology and Immunotherapy Department, 
CIMA, Universidad de Navarra, Pamplona, Spain
T cell migration within and between peripheral tissues and secondary lymphoid organs 
is essential for proper functioning of adaptive immunity. While active T cell migration 
within a tissue is fairly slow, blood vessels and lymphatic vessels (LVs) serve as speedy 
highways that enable T cells to travel rapidly over long distances. The molecular and cel-
lular mechanisms of T cell migration out of blood vessels have been intensively studied 
over the past 30 years. By contrast, less is known about T cell trafficking through the 
lymphatic vasculature. This migratory process occurs in one manner within lymph nodes 
(LNs), where recirculating T cells continuously exit into efferent lymphatics to return to 
the blood circulation. In another manner, T cell trafficking through lymphatics also occurs 
in peripheral tissues, where T cells exit the tissue by means of afferent lymphatics, to 
migrate to draining LNs and back into blood. In this review, we highlight how the anatomy 
of the lymphatic vasculature supports T cell trafficking and review current knowledge 
regarding the molecular and cellular requirements of T cell migration through LVs. Finally, 
we summarize and discuss recent insights regarding the presumed relevance of T cell 
trafficking through afferent lymphatics.
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iNTRODUCTiON
In an antigen-inexperienced host, the frequency of naïve T cells specific for any given antigen 
is extremely low, several thousand at most (1, 2). Given that the diversity of possible antigens 
is almost countless and that T cell activation requires direct contact with antigen, naïve T cells 
constantly circulate through secondary lymphoid organs (SLOs) in pursuit of antigen (1, 2). Upon 
encountering antigen in SLOs, antigen-specific naïve T cells proliferate and become activated 
effector T cells (Teff) that egress from SLOs and enter peripheral tissue at sites of inflammation 
(2, 3). Most Teff die after antigen is cleared but a few antigen-experienced T cells remain for long-
term protection and either develop into tissue-resident memory T cells (TRM), into central memory 
T cells (TCM) that recirculate between SLOs and blood, or into effector-memory T cells (TEM) that 
circulate through blood and home to inflamed tissue (1, 2). In addition to the abovementioned 
antigen-experienced cell types, regulatory T cells (Tregs) also circulate between blood, tissue, and 
SLOs (2–4).
Throughout the life of a T cell, the blood and lymphatic vasculature act as highways for T cell 
circulation. While much is known about T cell migration across and within the blood vasculature, 
much less is known about T cell migration into and within the lymphatic vasculature. Since the 
late 1950s, cannulation studies in sheep and rats have helped develop our current understanding 
of the cell subsets that circulate through lymphatic vessels (LVs). More recent technical advances 
BOX 1 | Tools to study T cell trafficking in vivo.
Tool Description Selected reference
Cannulation 
studies
This procedure involves the surgical insertion of cannula (tube) directly into an afferent or efferent vessel or into the cisterna 
chyli, to collect lymph fluid. The cellular composition of lymph is subsequently analyzed, typically by flow cytometry or 
microscopy methods
(5–9)
Adoptive transfer In adoptive transfer experiments, cells are isolated from donor mice, fluorescently labeled (unless already marked by 
endogenous expression of a fluorophore or a congenic marker) and intravenously or subcutaneously injected into a 
recipient mouse. In some cases, T cells are subjected to an in vitro culturing step (e.g., in vitro activation) prior to injection. 
At defined time points after transfer, T cell numbers in lymph nodes (LNs) (or other tissue) are quantified by flow cytometry, 
LN sectioning and microscopy, or other means. While this experimental setup is technically straightforward, the transferred 
cells may differ from the endogenously migrating populations. Also, typically only a small fraction of cells injected 
subcutaneously actually migrate to dLNs or beyond
(7, 10–13)
Intravital 
microscopy (IVM)
This technique allows the study of migratory processes at the single-cell level and in real time. It involves fluorescence-
based time-lapse imaging by, e.g., confocal-/multiphoton- or stereomicroscopy. Several mouse reporter lines expressing a 
fluorescent protein in lymphatic vessels (LVs) have been generated (14–18). In the case of T cells, most studies have been 
performed with fluorescently labeled and adoptively transferred T cells, but endogenous models are also available (19–21)
(22–26)
Intralymphatic 
injection
Microinjection of T cells directly into a LV upstream of a draining lymph node. Similar to adoptive transfer but permits the 
study of T cell entry specifically across the LN subcapsular sinus. This represents an elegant yet technically challenging 
method complementing IVM studies
(25)
LN egress 
studies
This experimental setup allows quantifying dwell time of T cells in LNs. In a typical experiment, fluorescently labeled T 
cells are first transferred intravenously into a recipient mouse. After an equilibration phase, further T cell ingress into LNs is 
blocked by administration of entry-blocking antibodies (e.g., directed against the integrin subunit α4 or against L-selectin). 
Antibody treatment allows the uncoupling of T cell entry from exit, which continues to occur. Exit rates, for example, can be 
calculated by comparing fluorescent T cell numbers in LNs at the time of antibody injection to a later time point (e.g., 24 h 
later; flow cytometry-based quantification)
(9, 22, 27, 26)
Photoconvertible 
transgenic mice
The use of photoconvertible transgenic mice permits monitoring the migration of endogenously labeled cells in vivo. It 
requires transgenic mice expressing a photoconvertible fluorescent protein in all cell types [e.g., Kaede protein (28) or 
Kikume Green–Red protein (29)]. Upon illumination with violet light, fluorescent proteins undergo irreversible changes that 
alter their fluorescent spectrum (typically a green to red shift). By selectively illuminating the tissue at a particular site (e.g., 
skin), one can subsequently quantify the appearance of photoconverted T cells in other tissues (e.g., dLNs) to gain insight 
about their trafficking behavior. The system can easily be combined with pharmacologic blockade of genes of interest. 
Alternatively, backcrossing onto a genetic knockout can be done
(28, 30, 31)
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(summarized in Box  1) have helped to further improve our 
understanding of the cellular and molecular mechanisms of 
T cell migration through LVs. In this review, we first introduce 
the structure of the lymphatic vascular system and summarize 
current knowledge of the cellular composition of efferent and 
afferent lymph. We then review the mechanisms by which T cells 
exit from lymph nodes (LNs) into efferent lymphatics as well as 
emerging knowledge of T cell entry and migration within afferent 
lymphatics. Finally, new insights regarding the overall relevance 
of T cell circulation through the afferent lymphatic vasculature 
are discussed.
STRUCTURe OF THe LYMPHATiC 
vASCULATURe
The lymphatic system consists of central and peripheral lym-
phoid organs and a LV network that permeates most tissues 
of the body (32, 33). In peripheral tissues, extravasated fluid, 
macromolecules, and leukocytes, i.e., the main constituents of 
lymph, are taken up by a network of blind-ended lymphatic 
capillaries, which converge into larger collecting vessels that 
drain into and through LNs (33). Upon passage through chains 
of tissue-draining LNs (dLNs), connected by adjoining collecting 
LVs, lymph is finally returned to the blood vasculature through 
the thoracic ducts, which merge into the subclavian vein (33) 
(Figure 1A).
Tissue fluid uptake and immune cell entry/transport into LVs 
is thought to mainly occur at the level of the initial lymphatic 
capillaries, where characteristic structural features support these 
processes. Lymphatic capillaries are composed of partially over-
lapping, oak leaf-shaped lymphatic endothelial cells (LECs) that 
are connected by discontinuous button-like cell–cell junctions 
(Figure 1B). Moreover, lymphatic capillaries are surrounded by 
a thin, highly fenestrated basement membrane (34, 35). Tissue 
fluid and leukocytes [as best shown for dendritic cells (DCs)] 
enter through the characteristic flaps between overlapping LECs 
(34, 35). Collecting LVs are structurally more specialized for fluid 
and immune cell transport (Figure 1C). Lymphatic collectors are 
composed of cuboidal LECs connected by continuous zipper-like 
cell–cell junctions and are surrounded by a continuous basement 
membrane and smooth muscle cell layer (34, 35). Intraluminal 
valves prevent the backflow of lymph, while contraction of smooth 
muscle cells helps to propagate lymph toward the dLN  (36). 
FiGURe 1 | T cell traffic through the lymphatic vascular system. (A) Recirculating effector-memory T cells in peripheral tissues ➀ enter afferent lymphatic 
vessels (LVs). The exact point of entry or the mode of intralymphatic movement has not been investigated so far. T cells that ➁ arrive in the lymph node (LN) 
subcapsular sinus (SCS) have been shown to cross the lymphatic endothelium into the LN parenchyma at the level of the ➂ SCS or of the ➃ medullary sinuses. 
Some T cells do not enter the LN parenchyma but ➄ directly exit through the efferent LV located at the hilus region of the LN. Recirculating naïve and central 
memory T cells arrive in the LN either via the blood (high endothelial venules) or via the afferent LV draining from an upstream LN (i.e., efferent lymph). ➊ T cells 
within the LN ➋ make random contact with the sinuses before entering and ➌ actively crawling or passively flowing within the sinuses. T cells were observed to ➍ 
cross the sinuses several times before finally being ➎ passively carried away into the efferent LV. T cells in the efferent LV circulate through downstream LNs 
before being returned to the blood circulation via the thoracic duct. (B) Lymphatic capillaries are composed of oak leaf-shaped lymphatic endothelial cells (LECs), 
which partially overlap and are held together by button-like associated junctional adhesion molecules (red lines). This setup creates open flaps through which 
leukocytes, fluid, and macromolecules enter into the vessel lumen. (C) LECs in collecting vessels have a cuboidal shape and are connected by continuous cell-cell 
junctions (red lines). Collecting vessels contain intraluminal valves and are surrounded by a basement membrane and contracting smooth muscles cells (orange).
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Collecting vessels enter the LN and convey lymph along the 
subcapsular sinus (SCS) and through the LN sinuses toward the 
efferent LV in the hilus region (37) (Figure 1A). Efferent lymph 
is then transported in the efferent collecting vessel to downstream 
LNs and is finally returned to the blood vasculature. Considering 
that LNs in mice and humans are typically arranged in chains (38), 
the efferent LV of a tissue-draining LN is conjointly the afferent 
LV of the next downstream LN. In this review, we will consider 
afferent lymph as lymph that has not previously passed through 
a LN, i.e., lymph that is derived solely from non-lymphoid tissue 
(as designated in Figure 1A).
CeLLULAR COMPOSiTiON OF LYMPH
Most of our current knowledge on the cellular composition 
of lymph extends from cannulation studies (see Box  1). This 
relatively simple surgical model allows collection of lymph under 
physiologic conditions from a defined area of drainage over 
long periods of time (6, 39, 40)—and therefore most accurately 
reflects the composition of cells circulating through LVs. In 
rodents, efferent lymph can be collected from the cysterna chili 
in mice (8, 9, 41), or by cannulation of the thoracic duct in rats 
(5, 42). However, due to the small size of afferent LVs in mice 
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and rats, cannulation of afferent LVs in rodents is very difficult. 
Correspondingly, most experimental studies comparing the 
composition of efferent and afferent lymph have been performed 
in larger animals like sheep (6, 7, 39, 40, 43–45).
efferent Lymph
Cannulation studies have revealed that thoracic duct lymph (46–
48) as well as efferent lymph collected after passage through one 
or more LNs is mainly constituted by T lymphocytes (6, 43, 44). 
More than 90% of lymphocytes in efferent lymph were shown to 
have initially entered the LN through high endothelial venules 
(HEVs) (39, 43). CD4+ T cells enter and recirculate through LNs 
more rapidly than CD8+ T cells (27). Accordingly, CD4+ T cells 
constitute the major cellular fraction in efferent lymph and out-
number CD8+ T cells at a ratio higher than that in blood (49, 50). 
Most T cells in efferent lymph collected from sheep exhibit a naïve 
phenotype, with a reported increase in the proportion of memory 
T cells in older animals (44, 51, 52).
Antigenic stimulation of LNs often leads to distinct phases 
in the efferent lymph response: an initial “LN shutdown” where 
lymphocyte output is decreased; a “recruitment phase” where 
lymphocyte output rises above resting levels; and a “resolution 
phase” where lymphocyte output and cellular composition return 
to resting levels (53–55). While in most cases a sequential egress 
of CD4+ and then CD8+ T cells has been reported (56–58), the 
dominance of a particular lymphocyte subset in efferent lymph 
appears to be dependent on the antigenic stimulus (45, 59–61).
Afferent Lymph
Compared to efferent lymph, the cellularity of afferent lymph is 
much lower (5–10%) under homeostatic conditions (6, 43, 44). 
While αβ T lymphocytes represent the most abundant cell type 
of afferent lymph (80-90%), DCs (5–15%), monocytes, B cells, 
and few granulocytes are also routinely found in steady-state 
afferent lymph (39, 43). CD4+ T cells in afferent lymph collected 
from sheep outnumber CD8+ T cells by approximately fourfold 
to fivefold (6, 43, 44). As reported in sheep, CD4+ T cells are the 
dominant cell type in afferent lymph collected from superficial 
dermal LVs of healthy humans (62–64). T cells in afferent lymph 
of both humans and sheep exhibit an effector-memory (TEM) phe-
notype, characterized by elevated expression of common T cell 
activation markers, adhesion molecules, and effector cytokines 
(44, 45, 63, 64). Although γδ T cells are present in large numbers 
in afferent lymph from sheep (65), they are almost non-existent 
in lymph or blood in humans (63, 64) and so are not further 
discussed here.
As cannulation of LVs is difficult in mice, a lot of our current 
knowledge of the T cell populations migrating through afferent 
LVs in mice has come from other experimental techniques used 
to investigate leukocyte trafficking (see Box 1). Specifically, these 
include adoptive transfer experiments or experiments performed 
in transgenic mice in which migrating leukocytes can be tracked 
by photoconversion of endogenously expressed fluorescent 
proteins [e.g., Kaede mice (28)—see Box 1]. Conclusions drawn 
from these approaches in mice are in accordance with earlier 
cannulation studies in larger animals. Moreover, they have 
revealed that the CD4+ T cell dominance in afferent lymph results 
from more efficient CD4+ T cell migration from the skin to the 
dLN (7, 31). In Kaede mice, the majority of CD4+ T cells that 
migrated from the skin to the dLN expressed the common T cell 
activation marker CD44 as well as the skin-homing molecules 
C–C chemokine receptor type 4 (CCR4) and E-selectin ligands 
(30, 31). Approximately 25% of CD4+ T cells that migrated from 
the skin to the dLN were also found to express the Treg transcrip-
tion factor FOXP3+ (30). Similarly, others have reported that 
adoptively transferred Tregs enter afferent LVs and migrate from 
the skin to dLN in mice (66–68). Notably, Tregs are phenotypically 
similar to TEM and are only distinguishable when specific Treg 
markers are used. The fact that FOXP3, the most widely used Treg 
marker, was only described approximately 13  years ago might 
explain why Tregs have thus far not been reported from cannula-
tion studies performed in sheep and humans (which frequently 
date back to earlier times).
In contrast to the conventional viewpoint that naïve T cells 
exclusively recirculate between blood and SLOs, low numbers 
of naïve T cells have also been found in both homeostatic and 
inflamed non-lymphoid tissues and have been suggested to circu-
late through afferent LVs (20, 69, 70). Indeed, in adoptive transfer 
experiments in mice, naïve T cells were shown to avidly migrate 
from the skin to dLN (7, 10). However, it is important to consider 
that the majority of endogenous CD4+ T cells in the skin have 
an effector/memory-like phenotype (10, 71). Correspondingly, 
cannulation studies in humans and sheep, and studies in Kaede 
mice, suggest that naïve T cells constitute only a minor subset of 
T cells in afferent lymph under both steady-state (30, 44, 64) and 
inflammatory conditions (12, 30, 72).
impact of Tissue inflammation on  
Afferent Lymph Composition
Cannulation studies in sheep have revealed that acute skin inflam-
mation, e.g., elicited by injection of complete Freund’s adjuvant 
(CFA), induced a dramatic increase in granulocyte numbers in 
skin-draining afferent lymph, whereas CD4+ and CD8+ T cells 
initially remained fairly stable (12, 53, 72, 73). By contrast, 
chronic inflammation, resulting from CFA-induced granuloma 
formation, was shown to lead to a substantial increase in CD4+ 
and CD8+ T cell output in skin-draining afferent lymph (12, 72). 
Contrastingly, in Kaede mice, an acute contact hypersensitivity 
response elicited a striking increase in the number of T cells that 
migrated from the skin to the dLN (30). However, it needs to 
be considered that numbers of T cells in steady-state lymph of 
laboratory mice might be unnaturally low, because of the sterile 
housing conditions that lead to the formation of a reduced pool of 
effector-memory T cells populating peripheral tissues (74).
ReCiRCULATiON OF T CeLLS THROUGH 
eFFeReNT LYMPHATiCS
Seminal studies performed in the late 1950s by Sir James Gowans 
were the first to show that lymphocytes constantly circulate 
between blood and SLOs (42, 46). Naïve T cells in the blood 
extravasate through HEVs into the LN via a multistep adhesion 
cascade and subsequently migrate to T cell areas in the paracortex 
TABLe 1 | Molecules regulating T cell exit from lymph nodes (LNs) through efferent lymphatic vessels (Lvs).
Molecule Selected reference Comment
S1P1/S1P (8, 9, 41, 77) S1P1-deficient T cells are retained in LNs; disruption of S1P gradient in 
LNs prevents T cell egress
CD69 (78, 79) CD69 expression induces S1P1 internalization and degradation in T cells 
resulting in T cell retention in LNs
C–C chemokine receptor type 7 (CCR7) (22) CCR7−/− T cells egress more rapidly from LNs whereas CCR7 
overexpressing T cells are retained
CXCR4 (80) Synergizes with CCR7 in retaining T cells in LNs
Leukocyte function-associated antigen 1 (LFA-1)/
intercellular adhesion molecule 1 (ICAM-1)
(26) CD4+ LFA-1−/− T cells egress more rapidly from LNs.
Common lymphatic endothelial and vascular endothelial 
receptor-1 (CLEVER-1)
(81) Blockade of CLEVER-1 reduces T cell binding to LN sinuses in situ
In vivo involvement not confirmed thus far
Mannose receptor (MR)/L-selectin (82) Blockade of MR/L-selectin reduces T cell binding to LN sinuses in situ
In vivo involvement not demonstrated thus far
α9 integrin (83) Blockade of LEC-expressed α9 reduces T cell egress from LNs
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(75). Following entry into the LN, intranodal position, migration, 
and motility of T cells are mediated by C–C chemokine receptor 
type 7 (CCR7) and its two chemokine ligands, CCL19 and CCL21 
(75, 76). Naïve T cells spend approximately 6–12 h surveying a LN 
for specific antigen and if undetected, transmigrate into cortical 
or medullary sinuses and exit through the efferent LV (28, 75). 
Below and in Table  1, we briefly review the chemotactic cues, 
adhesion molecules, and cellular processes involved in T cell 
egress from the LN into the efferent LVs.
T Cell egress vs. Retention: interplay of 
S1P1, CD69, and CCR7
Early findings that pertussis toxin (a natural inhibitor of Gαi-
protein-coupled receptors, such as chemokine receptors) inhib-
ited the export of mature T cells from the thymus (84), suggested 
that egress of T cells from the LN could also be an active process. 
Studies on the immunosuppressive activity of Fingolimod 
(FTY720), a now approved treatment for multiple sclerosis (85), 
incited further research on the molecular mechanism of T cell 
exit from LNs. FTY720 induces sequestration of lymphocytes in 
SLOs through retention and “log jamming” of lymphocytes on 
the abluminal side of the lymphatic sinuses, thereby inhibiting 
lymphocyte egress into circulation and migration to sites of 
disease (86–88). Besides histologic analysis of lymphatic sinuses, 
efferent lymph cannulation studies and LN egress experiments, in 
which T cell homing into LNs is first blocked and T cell numbers 
subsequently quantified over time, have been instrumental for 
studying T cell exit into efferent LVs (see Box 1).
Role of S1P
Several studies have shown that the egress-blocking activity of 
FTY720 can mainly be attributed to the action of FTY720 on 
sphingosine-1-phosphate (S1P) receptors, in particular, S1P 
receptor 1 (S1P1) expressed on T cells (8, 9, 89, 90). The natural 
ligand of S1P1 is S1P, an endogenous sphingolipid that mediates 
diverse cellular processes, including cell survival, cytoskeletal 
rearrangements, and cellular chemotaxis (91, 92). S1P levels in 
tissues are tightly controlled by sphingosine kinase 1 and 2 
(Sphk1/2)-mediated production and S1P degradation, which 
depends on S1P lyase and other enzymes (77, 93). While eryth-
rocytes, red blood cells, and the blood endothelium constitute 
major cellular sources of plasma S1P, lymph S1P is derived inde-
pendently from the blood (91, 94). In fact, LECs were identified 
as the major source of S1P in lymph (41).
S1P levels in the blood and in lymph are much higher than 
in lymphoid organs (77, 95). Low concentrations of S1P in 
lymphoid tissues and S1P abundance in lymph was shown to 
create a gradient across LECs, which induces transmigration 
of S1P1-expressing T cells into the lymphatic sinuses and egress 
into efferent lymph (93, 96): acting as a functional antagonist, 
FTY720 induces downregulation and degradation of S1P1 in 
T cells, thereby inhibiting S1P-mediated chemotaxis across the 
lymphatic sinuses (8). Similar to FTY720 treatment, adoptively 
transferred S1P1-deficient T cells were found to “log jam” around 
medullary and cortical sinuses and failed to egress into effer-
ent lymph (8, 9, 23, 41). An analogous egress defect could also 
be evoked when the S1P gradient in LNs was experimentally 
destroyed, by inhibiting S1P lyase (77), or upon genetic deletion 
of Sphk1 and Sphk2 in LECs (41).
Modulation of S1P1 for Fine-Tuning T Cell 
Transit Time through LNs
Similar to FTY720, high concentrations of S1P are capable of 
inducing S1P1 internalization in T cells (92, 97). Consequently, 
T cells in blood express low levels of S1P1 (95). Following entry 
into LNs via HEVs, T cells begin to upregulate S1P1 (95). Given 
that entry into LN sinuses, and subsequent egress from the LN, 
is S1P1 dependent, T cell transit time through the LN is in some 
manner dependent on S1P1-mediated resensitization to S1P in 
lymph. In addition to S1P-induced receptor internalization, the 
C-type lectin CD69 has also been reported to regulate S1P1 surface 
expression in T cells. CD69 is an early T cell activation marker 
and is upregulated in T cells by various inflammatory media-
tors, such as type I interferons (78, 93). CD69 has been shown 
to interact with S1P1, thereby inducing a receptor conformation 
similar to the ligand bound state, leading to S1P1 internalization 
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and degradation (78, 79). CD69 expression by recently activated 
T cells therefore serves to inhibit the egress promoting function 
of S1P1 (24, 78, 79). However, activated T cells only transiently 
express CD69 (98). Accordingly, once activated T cells have 
undergone several rounds of division and have downregulated 
CD69, they start to re-express S1P1 and appear in circulation 
(8, 22). Akin to CD69 regulated surface expression of S1P1 on 
recently activated T cells, T cell receptor signaling (the first signal 
of T cell activation) has been reported to induce transcriptional 
downregulation of S1P1 (8). Transcriptional restoration of S1P1 is 
also likely to regulate T cell egress during an immune response.
Role of CCR7
In addition to S1P1, CCR7 expression levels in T cells also 
impact the time T cells spend in LNs. Upon antigen recogni-
tion, activated T cells downregulate CCR7 (22). Fibroblastic 
reticular cells within the LN produce CCL21 and help generate 
a gradient where CCL21 levels are highest toward the LN center 
and decrease toward the peripheral medullary areas (25, 99). In 
addition to mediating intranodal positioning, migration, and 
motility (75), CCR7 also confers T cell retention within LNs 
(22). T cells devoid of CCR7 (CCR7−/−) egressed more rapidly 
than their wild-type (WT) counterparts, whereas transgenic 
T cells overexpressing CCR7 were retained in the LN for longer 
periods of time (22). Treatment with pertussis toxin restored 
egress competence of S1P1-deficient lymphocytes and in mixed 
bone marrow chimeras FTY720 treatment increased the number 
of CCR7−/− T cells found in efferent lymph relative to their WT 
counterparts (22). Collectively, these findings suggest that CCR7 
on T cells promotes their retention in LNs and that egress signals 
through S1P1 in part overcome CCR7-mediated retention (22). 
Interestingly, more CCR7+/− than WT T cells entered sinuses, 
suggesting that the interplay between CCR7-mediated reten-
tion and S1P1-mediated egress occurs at the level of entry into 
sinuses (22). More recently, it has also been reported that C–X–C 
chemokine receptor 4 (CXCR4) on T cells synergizes with CCR7 
to retain both naïve and activated T cells in LNs (80).
Adhesion Molecules involved in  
egress across Sinuses
While it is well established that adhesion molecules and their 
integrin ligands play an important role in T cell entry into LNs 
through HEVs (100), not much is known about their role in T cell 
egress across lymphatic sinuses. A role for leukocyte function-
associated antigen 1 (LFA-1) in delaying egress of T cells across 
lymphatic sinuses has recently been suggested. Following the 
probing of the surface of LN sinuses, CD4+ T cells devoid of LFA-1 
had a greater tendency to egress across sinuses and spent less time 
in the LN than their WT counterparts (26). This distinction was 
lost in mice lacking the major LFA-1 ligand intercellular adhesion 
molecule 1 (ICAM-1) (26).
In addition to LFA-1, the common lymphatic endothelial and 
vascular endothelial receptor-1 (CLEVER-1), as well as the mac-
rophage mannose receptor (MR) or its ligand L-selectin have been 
implicated in T cell migration across lymphatic sinuses: when 
performing adhesion assays on LN sections, antibody-mediated 
blockade of CLEVER-1 or MR reduced binding of lymphocytes 
to sinus endothelium (81, 82). However, the in vivo involvement 
of these receptors in LN egress has not been demonstrated 
thus far. On the other hand, a possible role for the integrin α9 
subunit in lymphocyte egress from inflamed LNs has recently 
been reported (83). Integrin α9β1 is a well-described binding 
partner of the extracellular matrix component tenascin-C, and 
both α9 and tenascin-C reportedly are upregulated in medullary 
and cortical LN sinuses during inflammation. The study revealed 
that tenascin-C binding to LEC-expressed α9β1 induced S1P 
production in LECs, establishing a mechanistic link between 
α9 integrin expression and S1P1-mediated T cell egress. In fact, 
antibody-based blockade of α9 or tenascin-C deficiency resulted 
in impairment of T cell egress from inflamed LNs, reminiscent 
of treatment with FTY720 (83).
Cellular insights into egress from intravital 
Microscopy (ivM)
T cell egress from LNs has not only been studied at the population 
level but also at the single-cell level using IVM (see Box 1). Such 
studies have confirmed previous histology-based studies showing 
that T cell migration and egress occurs both at the level of the 
cortical and medullary sinuses (23, 101). T cells were observed 
entering sinuses at multiple locations, however, occasionally two 
or more T cells entered at specific entry “hot spots” (23, 101). In 
cortical sinuses without flow, T cells migrated at the same speed as 
those in the parenchyma and occasionally exited sinuses back into 
the LN parenchyma (23, 24). In larger cortical sinuses with flow, 
T cells were more rounded, shared fairly uniform velocities, and 
had a lower frequency of exit back into the parenchyma (23, 24). 
T cells in the macrophage-rich medullary sinuses appeared to 
become poorly mobile and occasionally exited the sinuses and 
returned to the T cell zone (23). Following migration of T cells 
through cortical and medullary sinuses, T cells were released into 
the subcapsular region near the efferent vessel and moved off 
rapidly with lymph flow (23). Overall, T cell transit time through 
the LN appears to be determined by random walk encounters 
with lymphatic sinuses (24). Only at the level of the sinus do S1P1-
expressing T cells start to sense S1P in lymph, which triggers their 
exit into the lymphatic compartment (22–24).
T CeLL eNTRY AND MiGRATiON  
wiTHiN AFFeReNT Lvs
In comparison to T cell egress from LNs, little is known about 
T  cell migration from peripheral tissue into afferent LVs. As 
already suggested by the dominance of CD4+ over CD8+ T cells 
in afferent lymph (43, 44, 62), CD4+ T cells migrate more effi-
ciently through afferent LVs. Indeed, adoptive transfer studies 
(7), crawl-out experiments from murine skin explants (102), and 
studies in Kaede mice (31) uniformly demonstrate that CD4+ 
T cells more efficiently exit the tissue via afferent LVs. This is also 
reflected by emerging findings from many laboratories showing 
that under steady-state conditions most CD8+ T cells in periph-
eral organs form part of a slow-moving, skin-resident memory 
population [TRM; reviewed in Ref. (103, 104)]. Although recent 
TABLe 2 | Molecules regulating T cell migration through afferent lymphatic vessels (Lvs) into lymph nodes (LNs).
Molecule Selected reference Comment
CCR7 (7, 31, 114) Adoptively transferred or endogenous CCR7−/− T cells have reduced migration from 
peripheral tissues to dLNs
S1P1/S1P (10, 12) Treatment of adoptively transferred CD4+ T cells or recipient mice with FTY720 or S1P 
significantly reduces T cell migration to dLNs
CD44/mannose receptor (MR) (115, 116) T cell-expressed CD44 interacts with LEC-expressed MR during CD4+ and CD8+ T cell 
migration into afferent LVs
Common lymphatic endothelial and 
vascular endothelial receptor-1 (CLEVER-1)
(117) CLEVER-1 blockade decreases CD4+ and CD8+ T cell migration from the skin to the dLN
LT and VCAM-1 (67) Shown to mediate migration of nTreg from skin to dLNs
Macrophage scavenger receptor 1 (118) Regulates lymphocyte entry into the LN parenchyma
PLVAP (MECA-32) (13) Mediates lymphocyte entry across the subcapsular sinus into the LN parenchyma
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studies indicate that a similar tissue-resident population also 
exists for CD4+ T cells (31), many CD4+ memory T cells seem to 
rapidly traffic through the dermis, forming part of a recirculating 
memory population (31, 102).
Although several molecules involved in T cell egress through 
afferent LVs have recently been identified, we still know fairly 
little about this process, particularly at the single-cell level. In 
fact, thus far only DC, but not T cell, migration through afferent 
LVs has been visualized using IVM (see Box 1). Interestingly, 
these findings have revealed that migration into and within 
afferent LVs occurs in a stepwise fashion: DCs enter LVs at the 
level of lymphatic capillaries and then crawl in a semi-directed 
manner within lymphatic capillaries (105–107). Only once they 
have reached contracting lymphatic collectors do cells switch 
from an active to passive mode of movement, i.e., they are 
passively carried away with the lymph flow toward the dLN. 
Similarly, neutrophils were recently found to actively crawl 
within dermal lymphatic capillaries (108). The reason why 
intralymphatic DCs and neutrophils only flow in lymphatic col-
lectors is likely linked with the low flow conditions in lymphatic 
capillaries [reportedly ranging from 1 to 30 μm/s; (109, 110)], 
which are several orders of magnitude lower than blood flow in 
blood vascular capillaries (111) or peak lymph flow velocities 
measured in large contracting lymphatic collectors (112, 113). 
Although not demonstrated so far, it is therefore likely that T 
cell migration through lymphatic capillaries also involves an 
active, intraluminal crawling step (Figure 1A). In the following 
section, important molecules involved in T cell migration from 
the skin to the dLN will be discussed in greater detail (see also 
Table 2).
Chemotactic exit and Retention Cues: 
CCR7, S1P1 and Others
Classical definitions outline that non-lymphoid tissue homing 
TEM are devoid of CCR7 (119). However, in humans, CCR7 is 
expressed on the majority of T cells in blood, including those 
that express adhesion molecules required for homing to non-
lymphoid tissue (120). Consistent with these findings, 40–50% 
of all skin-associated CD4+ T cells in humans (121) and mice 
(31) express CCR7. Several studies have identified CCR7 and its 
ligand CCL21, which is constitutive expressed by LVs (107, 122), 
as one of the most important drivers of T cell migration to dLNs: 
adoptive transfer experiments (7, 10) and experiments performed 
in Kaede mice (31) have shown that compared to WT T cells, 
significantly fewer (in the order of 10–20%) CCR7−/− CD4+ or 
CD8+ T cells migrated from the skin to the dLN. Moreover, in a 
model of allergic airway inflammation, CCR7−/− CD4+ TEM cells 
accumulated in the lung and airways (114). Similarly, CD4+ TEM 
have been shown to accumulate within the epithelial tissues of 
CCR7−/− mice (123), and CCR7−/− Tregs accumulated in inflamed 
skin (124). Although CCR7 appears to be crucial for T cell exit 
from homeostatic and acutely inflamed skin, its contribution to 
T cell exit from chronically inflamed skin appears to be more 
limited (11, 12). In the case of DCs, IVM studies have recently 
revealed that the CCR7/CCL21 axis mediates DC migration 
toward and into LVs (106, 122) and also impacts the directionality 
of DC crawling within lymphatic capillaries (107). By contrast, 
the exact contribution of CCR7 to T cell migration through affer-
ent lymphatics has not been addressed so far.
Besides CCR7/CCL21, the second best described chemotactic 
pathway involved in T cell exit from skin is S1P1/S1P. As men-
tioned, LECs are considered the major contributor to S1P levels 
in lymph (41). Overexpression of S1P1 in CD8+ T cells prevented 
“settling” of TRM in the intestine, kidney, salivary gland, and skin, 
suggesting S1P1 enhanced exit via afferent LVs (125). Similar to 
S1P1-overexpressing CD8+ T cells, CD69-deficient CD8+ T cells 
failed to persist in skin after HSV infection, and treatment with 
an S1P1 agonist restored their retention within the skin (126). 
Correspondingly, surface expression of CD69 and transcriptional 
loss of S1P1 is a hallmark for CD8+ TRM (127–130).
In contrast to CD8+ TRM, tissue-resident CD4+ T cells have been 
less well characterized and studied. In a study using Kaede mice 
(see Box  1), Bromley and colleagues identified one population 
of CD4 memory T cells that remained in the skin and a second 
population, termed recirculating memory CD4+ T cells (TRCM), 
that migrated from the skin to the dLN (31). TRCM expressed 
a novel cell surface phenotype (CCR7int/+, CD62Lint, CD69−, 
CD103+/−, CCR4+/−, and E-selectin ligands+) and migrated in a 
CCR7-dependent manner (31). These cells displayed a traffick-
ing behavior distinct from classical TEM or TCM cells in such that 
TRCM migrated from skin to dLNs, and from circulation back 
into sites of unspecific cutaneous inflammation (31). The role of 
S1P in CD4+ T cell egress from skin has been addressed by two 
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other recent studies (10, 12). Treatment of adoptively transferred 
T cells or of recipient mice with FTY720 or S1P significantly 
reduced T cell migration to the dLN (10, 12). Interestingly, acute 
inflammation was shown to increase S1P levels in the skin and 
also resulted in reduced migration of CD4+ T cells to the dLN 
(10). This suggests that acute inflammation might induce T cell 
retention in the tissue.
T cells that have migrated from the skin to the dLN display 
high expression of CCR7, CXCR4, and S1P1 (7, 10). In contrast to 
the involvement of CCR7 and S1P1, CXCR4 was reported to have 
no role in T cell migration from homeostatic (10) or inflamed 
skin to the dLN (11). By contrast, in a pancreatic islet transplanta-
tion model, CCR2, CCR5, and CXCR3 reportedly contributed to 
the migration of natural Tregs (nTregs) from the allograft to the dLN 
(66, 68). While LECs constitutively produce CXCL12, CCL21, 
and S1P (41, 131), they are also able to upregulate inflammatory 
chemokines under conditions of tissue inflammation (131, 132). 
This upregulation occurs in a stimulus-specific manner (131) and 
may serve to fine-tune leukocyte recruitment into LVs. Although 
not specifically studied so far, changes in the chemokine expres-
sion profile of LECs might also explain the reduced CCR7 and 
S1P dependence of T cell tissue exit observed from chronically 
but not from acutely inflamed skin (12). On the other hand, it 
has to be considered that most studies investigating T cell tissue 
exit have been performed using adoptively transferred T cells, 
which might not completely reflect the chemokine (or adhesion 
molecule) requirements of endogenous T cells.
Adhesion Molecules involved in entry  
and Migration within Afferent Lvs
MR and CLEVER-1
Few adhesion molecules have thus far been implicated in T cell 
exit from skin. The MR (82), which has been shown to mediate 
T cell binding to lymphatic sinuses in LNs (82), is also expressed 
on efferent and afferent LVs (133, 134). Interaction of MR with 
its T cell-expressed binding partner CD44 reportedly mediates 
CD4+ and CD8+ T cell exit from the skin (115, 116). Similarly, 
CLEVER-1 is expressed on both efferent and afferent LVs and 
has been shown to mediate T cell entry into afferent LVs (81, 117, 
135). Blockade of CLEVER-1 markedly decreased CD4+ and 
CD8+ T cell migration from the skin to the dLN in both mice 
and rabbits (117).
VCAM-1, Selectins, and Their Ligands
A recent study suggested a role for LEC-expressed VCAM-1 in 
homeostatic migration of nTreg but not of naïve CD4+ or CD8+ 
T cells from skin to the dLN (67). VCAM-1 is a known target 
of LTβR (136) and blockade of LTβR reduced nTreg exit from the 
skin (67). Similarly, fewer nTreg devoid of the LTβR ligand, LTα, 
exited from the skin (67). As with ICAM-1, VCAM-1 expression 
is induced on afferent LVs during inflammatory conditions (131, 
132). Whether VCAM-1 might more broadly support T cell 
migration through afferent LVs in the context of tissue inflamma-
tion remains to be determined. With regard to the involvement 
of selectins, T cell migration from homeostatic skin to dLNs was 
found to occur normally in mice lacking the ligands for P-, E-, 
and L-selectins or upon adoptive transfer of CD62L−/− T cells 
(10). However, it is noteworthy that P-selectin is also upregulated 
on afferent LVs during contact hypersensitivity-induced inflam-
mation (131). This raises the question whether inflammation-
induced selectins and their ligands might play a role in T cell exit 
under inflammatory conditions.
insights into T Cell entry into the LN  
from Afferent Lvs
While several studies highlight the entry of T cells through HEVs 
or the migration of T cells within LNs (75, 137), few have focused 
on the entry of T cells into LNs from afferent LVs. Braun and col-
leagues investigated this entry pathway by performing time-lapse 
imaging in the popliteal LN following microinjection of T cells 
directly into the cannulated afferent LV (25). This study revealed 
that most naïve CD4+ T cells were passively transported in the 
SCS to peripheral medullary sinuses where they either directly 
transmigrated, or first crawled within the peripheral medullary 
sinuses before transmigrating into the LN parenchyma at the level 
of the medullary sinuses (25). As reported for T cell egress from 
the LN parenchyma into lymphatic sinuses (23, 101), several T 
cells occasionally crossed the sinus floor at specific transmigra-
tion “hot spots” (25). Interestingly, naïve CD4+ T cells entered 
across the medullary sinuses in a CCR7-independent manner, 
but subsequently preferentially migrated within the medulla 
toward the paracortical T cell zone by means of a CCR7-skewed 
random walk (25).
In contrast to T cells, injected DCs were able to directly trans-
migrate the SCS floor of the LN, allowing for a more direct access 
of the LN parenchyma (25). On the other hand, T cells injected 
after pre-injection of DCs now transmigrated the SCS floor on 
the afferent side of the LN and avidly migrated inward at sites 
of DC transmigration (25). These findings suggested that DCs 
induced local changes in the SCS floor during transmigration 
that facilitated direct entry of T cells into the LN parenchyma. 
Considering that afferent lymph typically contains both T cells 
and DCs that arrive simultaneously in the subcapsular space, it 
will be interesting to further explore LN entry from afferent LVs 
in an endogenous setup.
Other studies have suggested that T cells might enter the 
LN parenchyma directly through the SCS: as early as 4 h after 
adoptive transfer into the footpad of mice, T cells could be 
detected within the LN parenchyma in close proximity to the 
SCS (13,  118). Moreover, macrophage scavenger receptor 1, a 
molecule expressed on LECs of the SCS, but not on the medullary 
or cortical sinuses, was recently found to regulate lymphocyte 
entry into the LN parenchyma (118). Furthermore, the same 
group previously reported the involvement of plasmalemma 
vesicle-associated protein (PLVAP, also known as MECA-32) in 
lymphocyte entry across the SCS into the LN parenchyma (13). 
PLVAP is expressed by LECs in lymphatic sinuses where it forms 
diaphragms that overlay the entry to the FRC conduit system. 
This generates a sort of molecular sieve that restricts the access 
of soluble antigen into the conduit system and hence into the 
LN parenchyma. Interestingly, PLVAP also appeared to regulate 
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T cell entry into the LN, supposedly by supporting transcellular 
diapedesis across the SCS (13).
PURPOSe OF T CeLL MiGRATiON 
THROUGH AFFeReNT Lvs
As we gain more insight into T cell trafficking through LVs, 
our knowledge regarding the biological significance of this 
migratory process continues to grow. In the case of migration 
through efferent LVs, there is overwhelming evidence that this 
migratory step is crucial for immune surveillance: naïve T 
cells and TCM constantly recirculate through blood, SLOs, and 
lymphatics in pursuit of antigen (1–3). Blocking this important 
migratory step, e.g., with FTY720, inhibits T cells recirculation 
and represents a powerful strategy for inducing immunosup-
pression, e.g., in the context of autoimmunity. On the other 
hand, recent data indicate that T cell trafficking through afferent 
LVs may not only occur to promote immune surveillance but 
may additionally have immune-dampening effects and serve to 
avoid overshooting T cell-mediated inflammatory responses. In 
the following section, these hypotheses shall be discussed in 
greater detail.
Role of T Cell Circulation through Afferent 
Lvs in immune Surveillance
T cell recirculation through afferent LVs is thought to contribute 
to immune surveillance by constantly replenishing the T  cell 
pool in peripheral tissues with new antigenic specificities. 
However, increasing evidence suggests that recirculating T cells 
do not provide complete protection of peripheral tissues, and 
that TRM play a more important role in this process (104, 138). 
Although mainly studied for CD8+ T cells and in a limited 
number of infection models, TRM (typically CD69hi, CD103hi, 
E-cadherinhi, S1PRlo1 , and CCR7lo) have been shown to provide 
immediate protection against reinfection (104, 139). Current 
evidence suggests that TRM differentiate from Teff, remain resident 
within the tissue for long periods of time (>1 year in mice) and 
predominate at sites of infection or inflammation (104, 140, 141). 
Although there is some evidence that TRM proliferate locally, it is 
unknown whether TRM are ever replaced by circulating T cells 
(139, 142, 143). The protective mechanisms of TRM are not yet 
fully known, but evidence suggests that TRM functionally delay 
pathogen spread and further act as an antigen-specific sensor 
that “sounds the alarm” for the recruitment of circulating T cells 
(104). The relative contribution of resident and circulating T cells 
in pathogen clearance remains unknown and might be highly 
context dependent, e.g., dependent on the type of infection and 
the specific requirement for CD4+ or CD8+ T cells for immune 
control (104, 139).
Role of Treg Tissue exit in Controlling 
immune Responses in dLNs
Previous studies have shown that the local ratio of Tregs to Teff 
at inflamed sites is a critical determinant for the outcome of 
inflammation (144–146). In support of this notion, adoptively 
transferred CCR7−/− Tregs that accumulated in the skin of mice 
controlled Th1-mediated inflammation more efficiently than 
WT Tregs (124). While these findings suggest that retention of Tregs 
within peripheral tissue promotes resolution of inflammation, 
large numbers of Tregs reportedly exit the skin during a cutaneous 
immune response in mice (30).
CD4+ Tregs control both priming and expansion of Teff in 
SLOs and the activation of Teff in the skin (147–150). Several 
islet allograft survival studies highlight Treg migration to dLNs as 
a prerequisite for efficient downregulation of the ongoing allo-
graft response (66–68, 151). Only Tregs within the skin, or having 
previously exited the skin via afferent LVs, reportedly displayed 
an activated phenotype (66). Upon adoptive transfer of egress-
incompetent Treg into the graft, graft survival was shorter than that 
for WT Tregs (66–68). Similarly, in a study using Kaede mice, Tregs 
that migrated from inflamed skin had an activated phenotype, 
inhibited immune responses more robustly than LN-resident Tregs, 
and were able to recirculate back to the skin (30). These findings 
suggest that Tregs that have exited the skin via afferent LVs restrict 
LN immune responses (and consequently tissue inflammation) 
and recirculate back to inflamed tissue to help further control 
local immune responses.
Role of Tissue exit of Bystander T Cells 
in Resolving Local inflammation
The extent of tissue inflammation often correlates with the 
number and composition of infiltrating T cells, which itself is 
dependent on T cell recruitment from blood, survival in the 
tissue, and, last but not least, on T cell exit through afferent LVs. 
Interestingly, two recent studies have shown that the ability of 
T cells to exit inflamed tissues has an impact on the degree of 
tissue inflammation. In mouse models of delayed-type hyper-
sensitivity and TNF-driven Crohn’s-like ileitis, reduced exit of 
CCR7−/− T cells from the site of inflammation translated into 
enhanced and prolonged inflammation (152, 153). Similarly, 
T cells overexpressing CCR7 had an enhanced capacity to exit 
from inflamed skin and accelerated resolution of inflammation 
(152). However, depending on the experimental setup, these 
experiments might have to be interpreted with caution because 
of the confounding influence of autoimmunity observed in 
CCR7−/− mice, which might be due to other factors in addition 
to limited exit from peripheral tissues (76).
While recruitment into tissue is independent of the antigen 
specificity of T cells (154, 155), exit of T cells from inflamed tis-
sues appears to be at least in part antigen dependent (152, 156). In 
a mouse model of delayed-type hypersensitivity, transgenic CD4+ 
Th1 cells, co-injected with DCs that were pulsed with cognate 
antigen, displayed reduced migration from inflamed skin to the 
dLN relative to polyclonal CD4+ Th1 cells (152). Similarly, a 
significantly reduced number of antigen-specific cytotoxic CD8+ 
T cells (Tc1), in comparison to antigen-unspecific Tc1 cells, 
migrated from the lung to the dLN in influenza-infected animals 
(156). These findings suggest that upon recognition of antigen, 
T cells have an impaired “tissue exit program” and are retained at 
the effector site, while antigen non-specific bystander T cells con-
tinue to exit via the afferent LVs in a CCR7-dependent manner 
(156). This mechanism is likely in place to reduce unnecessary 
tissue damage through bystander T cells.
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CONCLUSiON AND OUTLOOK
In addition to cannulation studies, which have for more than 
six decades provided insights into the cellular composition of 
lymph, newer techniques such as adoptive transfer studies, LN 
egress studies or experiments performed in Kaede mice have 
considerably accelerated our recent gain of knowledge regarding 
the molecular mechanism of T cell trafficking through LVs. At 
the same time, IVM studies have provided further insight into 
the dynamics of these processes, by visualizing the single-cell 
behavior and anatomic location of T cell migration toward, 
across, and within LVs. While T cell egress from LNs into efferent 
LVs has been quite intensively studied, we still know comparably 
little about T cell migration into and within afferent LVs, or 
about the subsequent T cell entry step into the parenchyma of 
a dLN. In the future, it will be important to better characterize 
the distinct T cell subsets migrating through afferent LVs and the 
molecules involved in their trafficking. Moreover, the importance 
of tissue-resident vs. recirculating memory T cells will need to 
be addressed in more models. Given that CD4+ T cells constitute 
the main cell types recirculating through afferent LVs, this will be 
particularly relevant in the case of CD4+ T cell-dependent immu-
nity. At the same time, it will also be important to carefully chose 
the right animal models when studying these processes: the fact 
that only few memory T cells are present in peripheral tissues of 
laboratory mice held under optimized hygienic conditions, and 
that these mice respond differently to immunologic challenges 
in comparison to mice housed under less hygienic environments 
(74), indicate that our preferred experimental setups might not 
represent a faithful model for studying the importance of recir-
culating vs. tissue-resident T cells in immune recall responses. 
On the other hand, we also still know very little about the 
potential function of recirculating T cells in dampening acute 
immune responses, possibly via tissue exit of Tregs or of T cells 
with irrelevant antigenic specificities. Recent observations that 
migration of DCs and neutrophils through afferent LVs involves 
active semi-directed migration within lymphatic capillaries sug-
gest that the migratory process itself is more complex and might 
serve other purposes than the mere transport of cells to the 
dLN. Thus, in spite of recent advances regarding the molecular 
control of T cell traffic through LVs, we still know little about the 
biological relevance of these processes, particularly with regard 
to migration through afferent LVs. Ultimately, more insight into 
both the molecular mechanisms and the relevance are expected 
to contribute to identifying new targets for immunomodulatory 
therapies.
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